Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITK | Q08881 | 10/20 | 0.46 |
| ▸ | INSR | P06213 | 8/20 | 0.46 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 2/20 | 0.39 |
| ▸ | GRM1 | Q13255 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6270096 | 0.86 | GRM2 (0.49) | ITKINSRGRM2EGFRGRM1 | |
| SCHEMBL21310824 | 0.83 | ALDH1A1 (0.37) | ITKINSREGFRALDH1A1POLB | |
| SCHEMBL6420360 | 0.80 | ITK (0.47) | ITKINSREGFRALDH1A1POLB | |
| SCHEMBL6273961 | 0.78 | ITK (0.52) | ITKINSREGFRALDH1A1POLB | |
| SCHEMBL6273966 | 0.78 | ITK (0.45) | ITKINSREGFRALDH1A1POLB | |
| SCHEMBL21310820 | 0.78 | TLR8 (0.43) | ITKINSRALDH1A1POLBHTT | |
| SCHEMBL21310846 | 0.78 | RPS6KA5 (0.47) | ITKINSREGFRALDH1A1POLB | |
| SCHEMBL6418932 | 0.76 | ITK (0.54) | ITKINSREGFR | |
| SCHEMBL21310752 | 0.76 | EGFR (0.39) | ITKINSREGFRALDH1A1POLB | |
| SCHEMBL21310917 | 0.76 | EGFR (0.54) | ITKINSREGFRALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050209284-A1 | Tec kinase inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | US | disclosed |
| WO-2005079791-A1 | THIOPHENE -2- CARBOXYLIC ACID - (1H - BENZIMIDAZOL - 2 YL) - AMIDE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE TEC KINASE ITK (INTERLEUKIN -2- INDUCIBLE T CELL KINASE) FOR THE TREATMENT OF INFLAMMATION, IMMUNOLOGICAL AND ALLERGIC DISORDERS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209284-A1 | Tec kinase inhibitors | TEC, ITK, TXK | ITK 2/4885INSR 910/4885GRM2 3383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.